Sanofi-Aventis SA said that its offer for Genzyme Corp has been accepted by shareholders representing 84.6% of the company’s common stock and approximately 77% of shares on a fully-diluted basis, giving the French company full control. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
